| John Mullaly | IR |
| Jennifer Bath | President and Chief Executive Officer |
| Lisa Helbling | Chief Financial Officer |
Good morning, ladies and gentlemen, and thank you for standing by. Welcome to ImmunoPrecise Antibodies Fiscal Year 2022 Third Quarter Earnings Results and Business Highlights Call. Currently, all participants are in a listen-only mode.
Following the presentation, we will answer pre-submitted questions. [Operator Instructions] I would like to remind everyone that this conference call is being recorded today, March 16th at 10:30 AM Eastern Time. call John the turn now over Mullaly. to I’ll Mr. please go ahead. Mullaly,
Financial Bath, and and Chief Chief answering the pre-submitted welcome. summary Q&A you follow the call. President on Ms. will today’s speakers Dr. Helbling, questions Antibodies; Thank remarks. period ImmunoPrecise quarter Jennifer and followed A closing be of Executive Lisa their will Officer of Officer by
would I to by regarding performance, its Bath may materially expectations or or begins, these forward-looking have from several the preparing to I obtained read ImmunoPrecise of or other forward-looking are following Dr. by made contain Antibodies by differ intentions, statements, goals risks been and that Before ImmunoPrecise current that everyone Harbor the and developments. activity, actually company Safe statements. there results today plans, In those future events ImmunoPrecise like will remind asked results, and remarks forward-looking levels were future statements. about achievements statements assumptions
As reliance information will undue Discussion materialize forward-looking investors and a are the any its forward-looking of today refers place you to EDGAR cannot statements company to cautioned not www.sec.gov. and on them. current consequence, Analysis at and and ImmunoPrecise statements to www.sedar.com potential that Management issued at section on guarantee the and
whether to securities Bath. to statements Forward-looking would now ImmunoPrecise's forward-looking I does ImmunoPrecise laws, conference not future turn by a Except XXXX. update events the over undertake new required any information, represent statements obligation otherwise. maybe expectations as XX, result of like Dr. as or any to of March as
call you thank today. and morning joining for Good John. IPA’s you, investor Thank
of Talem CRO also and our you to confident business. update period IPA’s this organization key strategic reporting teams, have We've to and We bring execution plan. services. and with sales awareness fill across roles growth in generation helping from business ability both next pleased lot business revenues wins, continued the We clients’, development We're through marketing continued ramp existing progress within to the from operating the emerging a global on of our and Therapeutics. new the our sectors and grow remain to to tackle
merit key our inflection several to as points. gain pipeline value continues advance toward worth assets and Additionally, Talem
we development our multiple fronts, company's XX.X% up to our in-house CRO this TATX-XX quarter, pleased the start year. as Lastly, will the forward in partnering, report PolyTope some that period are review through performance to the call. with detail which is this moving of We're external same on on discuss both compared revenue and a we We'll business. project of last
than As discovery and enhancement of Thus expansion saving irrelevant ongoing we actively taught XXX and XXXX first time IPA sequences us first partners each lead attributable function of attention sequence These steady timelines worth the are function its and the continue contract. decrease focused and CRO from and addition The antibodies. technology time upward candidate functions what addition size capabilities and projects functionally relevant or value we pharma function top in see both IPA's that growing efficiently clinically is by our workflows grow the clients to platforms of particularly significantly from eliminating B options, spent of cost elevate are is to first on more catching with companies. IPA’s, Select under technologies, respect money. that we business, call and competing sequences increased growth interest to identifying the number partially and the candidates Cell delivered. tactically and biotech
come. platforms the in more to surely about hear first You'll these function months
development this quarter including workflow, functional bioassay our generating of addition revenue our assays. value services to was Another the high
function prior cells first allows workflows, at in a from the bioassays forward. critical moving volume specific in platform workflow be Such on particular assays the our the corresponding surface directly reduce antibody earlier accessibility internalization, directly receptor taken triage This directly test of past and functional determine or if screening data the lead is concentration with other isolated unlike campaign. to access into the bioassays antibody relevant this competitors its present functional most samples because, target designed allow This selection. ablate IPA which done partners on targets detailed discovery and possible used the candidate For antibody of receptor we ensures to the demonstrates can candidates the critical strategy IPA’s quarter cell. for to instance, the clinically to the one of activity the is integrated appropriate of B
catalog as sales increased mainly OEM our XX% differentiate Lastly, recent provider million, IPA's attention our will labs, of including same as individual ongoing through the sales continue some believe growth three launch the several offerings generation In year-to-date distributors, currently to of the the product due and last web future research is products QX period IPA's. quarter of organoid into to orders. about catalog revenue our and offers highlighting to the within catalog IPA's services. our discussion, extended benefit turn are year. to innovation high same organoid of in compared now new $XXX,XXX expanding in sales shop fiscal adding significant to compared leading by drivers the will which different particular, in period to due year, sales which $X.X this an large increase of in in for factor growth need we The addition ultimately last drove our additional different is revenue this cumulative IPA next advances, factors year, streamlining to increase increases I considering IPA of Asia the sales. of IPA expansion of the products catalog distributors, purchase for our demand. also these we
background point an antibodies a characterizing step place binning target epitope molecule is would information out grouping a binds. that one, probably of the to to you'll content with on which which is sign investor importance you This up series, on antibodies starting the the receive can for like in topics Primer. a like IPA region called heard us receive critical IPA's and and blog likely website, you among the a first our if our which this antibody other You've what's newsletter on Science talk about on science called good to is based
And Antigens, move was functional IRAP implementation The various assays, ability of Okay, known diversity Research sequencing unique This IP service provides classify and their sourcing in to and responding programming request beyond traditional so increased This diverse to developments sample transgenic for really cell discovery efficient until we sample early-stage of and sets It's can binning In of funding important antibodies, capabilities year of such repertoire Canada an characterization thinning efficient research. their IPA of to enables science antibodies bind XXXX. meaningful particular information immunotherapies for CRO epitope therapeutic usage, protection. I and animal to and general are the produced broaden back epitope. say that and generation specific to and human some of for panels resulting important are refined past a on important more the workflows class maintenance services this epitope. support all site specifically access chicken fully binning faster antibodies quarter Victoria to preferences faster. particular the National be the therapeutics delivering period quarter right based as antibodies In uncharacterized assets generations. third These antibody awarded polyclonal simpler the our characterize screening for refined of mediated possibly of called We're versatile in of more we're an larger will client more are in our targeting genetic selection also demand FC ways the of Camelidae support other clinically oncology. expansions of rare into next function, to difficult And the from medical enable the rabbits, candidates. though, the associated initiatives, and proteins is clinic to But by that that here also broader to in portfolio. capable the relevant that conditions epitopes nonspecific of their discovery. which cells. this earlier as customized are the terms following interest are particular advanced such llama types and genetic brief, meet horizontal multi-species, now. lump for lastly We Council and targeting to of workflows, effector immunization for not an as certainly of for B from a development the we of serum. immunization. includes CRO non-rodents cannot increased to unmet human used fiscal should and next capabilities identifying our support in areas as in have world at cover of strains grant llamas and all demand these evaluation Neo to These our NGS can Of for the cancer fully with confused the advances more therapies antibody omics-based of proteins rest business. offered the of note commonly our exciting technologies or expansion especially into IPA’s is of advancements
targets including go engagers areas. of therapeutics are and NK therapies, We that precision engagers are the and which on interest two and immuno-oncology cell of beyond working medicine cell challenges to traditional cancer immuno delivering other immune great
the these novel with the expediting increased stated as speed. earlier, of Additionally, of and AI, are targets selection we also with advancement efficiency
Therapeutics. Next, update turn PolyTope our an TATX-XX we our are to program. Talem to with attention on excited Starting
of our in as period. well the on concept last PolyTope TATX-XX in-vitro published We as preclinical both have proof data lead candidate updates,
work targeted currently year. and is website. subsidiary. but capabilities not expect with FDA as As Therapeutics, antibody This provide to submit IND for summary leverage PolyTope being and generation IPA's timeline Talem TATX-XX We'll shows to QX you slide access calendar discovery and our the well capitalize by programs ongoing cocktail completed assets. of information in we potential the TATX-XX on of asset. house submission QX SARS-CoV-X to our partners proprietary also discovery We're customers, showcases this Talem TATX-XX our allows and this also or developed as well IPA's and for this on you only developed to know, against antibody to first in- our us a Talem progressing
year. And of The complete successful. and the and PolyTope is a TATX-XX is In Analysis pharmacokinetics manufacturing the the we screening for of study. on on portion summarizing of expect is it work, toxicity ongoing the pivotal preclinical terms study is was we are of currently PK of results planned schedule. ongoing currently the GLP human tissues off target calendar quarter are second trial around the completion initial human
to have believe of the to been variants of TATX-XX the cartel, development address data in We discussed potential the preclinical remained based variants has in demonstrates and feedback, very other PolyTope intentional that the COVID of announced it well. our known we concern. as IPA design lockstep to-date doing FDA has continual and which also positive. SARS-CoV-X conversation the with of previously so FDA currently on TATX-XX future strong has has potential address in with And been
As up submission mutants, have development commentary. important that and came viruses a vital direct that enabling maximizes is which process. the recognize is development studies a built needed contrast doing for not concern. spend scientifically on a at When it our program inquiries new of literally variant and from IND it as thus derisking these of variant in It's additional in programs impossible arising not emerge generate feedback lifesaver. our late in our pre-IND natural FDA weigh development a IND out out setbacks infection in our rise and mutant PolyTope around We evade existing method a will setbacks This to will result R&D experienced immunity. any and to backtrack be rates believe can result, so, hospitalizations a of mutants value FDA to a as scientific have that process adverse COVID approach or sessions, predict feedback. to with we experienced skipping of immunity, FDA as result similar predict this new whether turn goals TATX-XX of will our allowing the developmental while to based is the risk on a to No escaping again
unvaccinated were mass product The action. left potential not deaths the Despite start XXX% challenge numbers and is targeting Coronavirus like Center. it viral not the to ineffective the based campaigns, immune fill by and part reporting that prime month are USA vaccines responds has conserved individuals parts the unique represent from Our system Resource X.X XX,XXX shown multiplying system. on of mechanisms and foothold, gain therapies multiple alone by This booster has do These because the vaccine and through multiple there vaccination effective over and of relatively COVID-XX spike Coronavirus gap immune cases the protein million any in each vaccine and and a in is differently. can exclusively. other the last
the addition antibody its antibody is determining important antibody person which the that how is titer vaccinated to. is strong exposed breakthrough In epitope the and affinity which the as to binds to and how amount well avidity factors is virus are binds of in
potential continuous infections certain provided diabetes, inadequate HIV Infections and syndromes, linked death. chronic time. heterogeneous are a shots and more potential of a chronic obesity, booster rheumatoid breakthrough In supplementary heart, outcomes transplantations, to This individuals progress likely these arthritis, addition, related as users also to disease is and immunocompromised Core These pulmonary XX individuals are to system. increasing syndrome. TATX-XX. to of years certain risk immunity prevent such over acquired liver why or ages frequent the congenital and always kidney is problems, of are with severe morbid threat There's with and immunotherapy greater. of group to is growing down malignancies, and associated immune which diseases, non-enduring, are disorders, organ COVID-XX users
the anyone individuals X.X% reported the the Alzheimer's already apparently schizophrenia. from of and for [indiscernible] reported of if the U.S., co-workers for using is that by and statistics immunosuppressive references available are also suffering are outcomes And estimate scarcely X% available interested. The reasons, population these unclear immunocompromised. approximately as in drugs population For is is XXXX. In part
therapeutics in CDC really outbreaks, during of sub-variant cases important approximately is ago. just nearly in the estimated efficacious Just the sustainability one the that yesterday, and is mutation? virus what of the monitoring Omicron northeast, the cases only from or to of U.S., diagnostics outbreaks, new the up monitoring new XX% also So of updated of and is but continual continual new maintaining the week BA.X of cases in XX% XX% remain
even therapies which different of antibodies the together. concern. of comprising cocktail all fact and companies variants for binding how the and dual that to of original potency retained when the is studies. variants Equally only from viruses last continuously tremendous studying so dropped are Also binding in maintain TATX-XX variants. noteworthy a into Omicron its the four TATX-XX cocktail clinical the toward the the Omicron TATX-XX virus concern, toward of of variant different the We showing protein, it resilience announced is of PolyTope many the all efficacy from some spike other feat not increased to neutralizing did many emerging We tested efficacy out, therapies neutralize neutralization showed mono the previously pseudo commercial variation retain impressive, but very little given power the
today We BA.X drug military our to agency, binding partner that due silico and would setting. TATX-XX. And Omicron for dosing uses, BA.X you've that Research cell our hope against Switching share the BA.X on delivery on both to testing exciting the these TATX-XX access a a will data also company In molecular an based retention a of the by modeling joining sustainable innovation anticipate potently will Elektrofi bind ongoing for protein. concentration in and and to bit. Innovation gears support We collaboration that biotechnology still package neutralizing forces, data we we're remain therapy the of explore associated formulation currently individual collaboration was for formulation individuals selected with Boston defense have of a therapeutic DHA Elektrofi an therapies the This with easily hypothesis news antibodies studies, spike After high and ideally frequency proud contract version Elektrofi in of to focused rapid and diligence are completed health product prophylaxis. high the PolyTope many seen supports spike self-administered TATX-XX prophylactic IPA initial their suited we the deployment, which antibodies to independent program to that providing enabling protein. sub-variants. the to as with generate requiring a of immunocompromised Defense. Department formulated leveraging within aims IND operations, such Business alternatively including developing be for By Small non-healthcare modeling
existing Importantly, clinical to effort the directly an is collaboration current in to integrate being retain IPA's into timelines. designed program
performed currently lab observed LiteVax collaboration slightly data data to as certified study will with [indiscernible] LiteVax whether immunogenicity efficacy we determine immunogens the We're a second transect the whether also to of using a vaccine study. antibodies. our respect adapted a responses from with immune pig funded progress Based immune [indiscernible] funded quite indicated, the responses immunogen to promising. previously in awaiting binding decide these Regarding neutralizing animal are transect elicited a to and IPA with on
I'd Now to you closer more a internal Talem's a pipeline of look few give at like assets.
functional to being of different regression. selection. tumor is by based with interference lead ADC against receptor candidate at specific strategies signaling from chicken introduced we've variety The progress antibodies We'll monoclonal antibodies types on surface here few a on slides have diverse This programs, stage programs, on therapeutic of cover a since human TATX-XXX, several by a which one which and cell approaches the induce start are including with treat the of to stage investigated options, the of So two pipeline approaches, slide of cancer last a multiple called quarter. earlier derived advanced we'll program each lead TrkB. panel focusing TrkB and focusing nicely to or assets share
a a in for screenings multiple of functional see candidates with diseases. identification similar functions, enables enabling potentially treatment the antibody lead with As ELKX, strategy variety of you'll sets the implementing of different
introduced example, is neuro-related TrkB a specific receptor, diverse agonist such cells TrkB to endothelial disorders auditory antibodies a as transcytosis TATX-XX includes signaling, targeting you and panel an candidate ophthalmology. for LDL systems, value. scrutinized analysis to disease. we've a portion functional undergone block to As ELKX, or functional is derived the Alzheimer’s previously, of in which stage This the cardiovascular are being selection also early an lead antibodies are ability maximize treat of antibodies, their mediated being treat now of which from to resulting of investigated the disturbed variety program capabilities rabbit monoclonal have or
Here you in Antibodies cholesterol” proven treatment of with may pathological psoriasis. tumor LDLs, also “bad investigate anti-angiogenic are tumors. recognize being causing formation. blood ELKX effects [indiscernible] solid to vessel sought is the involved
next in antibodies on tumors. Some protein are alpha for and of right, several you update then lead TATX-XX, antibodies, is potential as as might healthy we've on program treatment. particular tissues membrane potential oncological the which agonist the also expression diabetic will our treat and retinopathy. we'd be investigated act like therapeutic In All a repertoire designed to profiles to targeted therapeutics based in the this and program, so
lead require investigations We use therapies a determine in under engineered known and very in anticipated further These cells produce The immunotherapy. candidates. also assets of genetically binding strategies. the use relevant epitope functional verification and activating are in molecules T which options to Therefore, for artificial combines candidates, for antigen two TATX-XX for as for receptor to Effector panel identify screening. landscape clinical kinetic function-based for antibody chimeric of cells, behavior T antigen vitro CAR both will receptor we conjugates the conditions binding are diversified cell T, drug and addition cell an designing T T as function.
cell a TATX-XX. recently to pH a is a which therapeutics in tumors on the involved This of potential cancer. development focuses protein regulation. program on launched enzyme a we solution The refractory is subset are of for Moving more including targeting membrane
recombinant will in we data and expression target set, oncology analyze discovery identified prioritized antibody clones therapeutic phase for functionality We for have From strategies. and binding currently antibody verification. select different leads XX this
of facilitate to immunotherapeutic. initiated TATX-XX cancer Lastly, was generation next delivery
T facilitate targeting Assets from with this appropriate tumor when killing an with combined bispecific a are cell program mediated anticipated to antibody arm. tumor
a own effector a the and body's We the other TATX-XXX. subset have this support to the with cell cell system antibodies specific malignant from tumor candidates XX in format. clearing will lead T engagement Currently, bispecific assets evaluation and combinations endogenous The in these itself. programs enable close to evaluate in as Talem based binding verification format we cell reporter proximity from the in intriguing cell therapeutic expected single antibody of the program value such is prioritize on a for of between immune assays bio
I'm our Netherlands. So for moving going the expanded on progress start first with facilities. to the to update on
premises is move lab out We by the aim Our to move in the to late test which laboratory team in is in spring schedule construction preparation infrastructure of will and The The the and when transfer building. Utrecht is the secure during early be its build the to install very for to on active runs and completion laboratories projects. completed in April, anticipated still the of is accelerator IT for to the new new summer. followed a the materials smooth commence. safe
facility to staff is preparing construction. move As currently which are O's previously under also announced a and to new
fit the tuning intended expansion it's sure with to line make in that of and fine are expected We out growth services. our
will all more recirculated the facility to month. the in exciting procedure room. help larger parallel. for to be and that to Canada's initiations and cell renovations The multi-method of power delays expansion increase while select of have square renovations ensures updates no and on in B will UV and The air This are of air. our XXX% be facility cohorts ability larger multi-stream expected usable HEPA the programs. adds complicated will filters be and and generator there doubles fully IPA’s the footage dynamic one program vivarium completed place place The Victoria, completed support program on trend took remained HVAC operational. is in will additional new also at the which this space of We renovation unit The end
in are strategic heart vision these an and our also We the a updates lead creative addition director for the quite few filling have planning important role articulating well. marketing team. with from as the of And marketing These we at of milestones. sales advancements initiatives and a our
and we initiatives balance the Additionally, CRO human framework, in grow seeking address growth, in to right of to business development continue gaps capital both scale. our properly the to
Another enhancing important the has the of growth of the Sales first Coast. a U.S. step in U.S. West in been market for hiring Director
and functional and a marketing channel initiatives awareness efficiency operational and saw The to and conference robust nimble vertical overhaul activation media quarter competitive in new for engagement across team includes efforts infrastructure major world-class support our this and quarter. social implementation Third to cross the with marketing This planning of a and audiences. ignite implementation platform event and brand launch a plans. and media communications execution and of other across key systematic planning key plan
news, social discuss discovery. the new We kick Boston such media engage like PEGS categories to conference that, speakers. to look more I'd over leadership, thought leading for and brand have topics with to build IPA instance, And gauge we've maintain to dinner in offerings, industry relevancy backdrops for activities updates, help and narrative with on between IPA forward initiated a market symposium Lisa to business as balanced weekly compelling will And host performance. fresh a and At the to of early activities several to call as the next the perspective in IPA, quarter's IPA's with a at existing potential and turn our May, biotherapeutic results. financial clients company upcoming to start both generation event social new and wrap community
all Helbling. to increase. January morning, dollars. CFO, to last company's X.X numbers in million the million I'm X.X XX, a of project and X.X was X.X Thank same period million, or the compared unless IPA's, revenues X.X% company's in XXX,XXX, year million revenue increase. to Canadian compared you, XX.X% Most notably, XXXX, XXXX, everyone. The referred total Jennifer, months otherwise ended Lisa three are the noted, good during
sale and As Total revenue the XXX,XXX leading with B contract cell product is Jennifer increases of the company's XXXX, XX, of by totaled select first a ended decrease of primarily months or under number last during months therapeutic January year. sales related XXX,XXX mentioned, asset. the generated of compared same quarter. antibody both higher driven the of The three growth sales to the its to projects expansion to the internally the during projects in period the XX.X%, XX, size for the XXXX ended XXX,XXX, three product January platform, company's
XXXX. gross attributed profit a X.X X.X the XX% margin distributors. with of profit launch as mentioned, million, the XX, and XXXX, profit product for of months our include, and increase new new enzymes, addition compared the Catalog product ended of three growth During antibodies, of gross in sales example, a website proteins to sales achieved The catalog January company's sales XXX,XXX. company was and Jennifer the in to million and XX% is gross
gross profit of quarter's our is expectations. within margin This XX%
as research XXXX, fiscal therapeutic required expensed a company XX, year January been developed cost sold the During antibody, that in the the ended first as had year internally IFRS. by already prior
new and previously company its two implementation of Reporting 'XX. Financial the Accounting during addition, as the system full a In for culminating in past ERP year fiscal improved years, the System reported, effective
company expense system the full expenses with was to been the the up of period primarily used miscalculate for third effect million January along operating five While that company's the to implementation its of same year. was million of were X.X million. due the expense X.X to XX, the make for have research to of increase the XX% restrictions and this of its compared and first the antibody compared period related and and were XXX,XXX of increase quarter ended to inter-company XX%, the expenses XXXX, correction, year of The an of a caused There X.X procedures processes sales XXXX, in XXXX, including company's This in can complicated increased Jennifer of eliminations and website. investment sale Research internal these development a found COVID-XX. in would the quarter to on and transactions PolyTope XXXX X.X cocktail, largest undertaking cost gross reduction the Talem. research discuss new a miscalculation for in travel complications that and development strategic in corrected These company's expense. margin sales research research was mentioned resulting I'll million be reduction to SARS-CoV-X XXXX, the in Talem's the by profit in XXX,XXX. due the projects that the order nil from of other Adjusting
XX, general the would to Salaries year, when the discussing addition that prior cash last an same same of held year. last that compensation gross the last expenses the lower year. and is the loss was period to for period expense insurance company. meeting miscalculation officers recently, quarter NASDAQ the to to on options foreign prior to January current mentioned, exchange last company at months payment exchange the of net listing The U.S. for the the period vesting result XXX,XXX also This net VP for had organic year effective of X.X the quarter a revaluations X.X was end and XXXX and premiums in margin, nil year The in three listing. D&O includes ended in XXX,XXX directors pay result relations insurance compared than of to million XXX,XXX XXX,XXX primarily based quarter the in decrease expense item annual most lower of benefits fiscal was currency granted company and growth primarily increases Last in year, last be and only for XXXX operations. strategic the to XXX,XXX, recorded of of Marketing due The same and lower regulatory year. is plans the a fees I gain compared Share higher support December after dollars VP the of the XXX,XXX company's NASDAQ loss is research period as X, XX,XXX is benefits XXXX. have and prior increase expenses incurred associated of million a than XXX,XXX of company's the company's and Office awarded profit September the same totaled compared the loss with The client XX, rate. research November. full unrealized increased leadership and same general noteworthy of unrealized exchange support year. costs X.X the XXX,XXX Total The roles the to company's as As occurred, year. increase to income the related summarized XXX,XXX. gain been period can million and the addition the million of routine for of X.X the X.X of to XXX,XXX XXXX. This from and of increase primarily increase gross The the profit to strategic salaries compared other investment the compared year. a
as a that insurance found higher increased The which over of the first made period compared increase antibody, includes addition from totaled million to and period year of company's and expensed its period. year, increase including listing sharing expenses use expenses. its XX, and XXX,XXX is XXXX, to in primarily research company of in driven my roles, company X.X therapeutic over compared increase of largest the payments than awards contract, research under gained strategic and strategic during leading the were fiscal expense its nine the XXXX, the expansion development leadership with distributors. XXX,XXX the during Higher were XXX,XXX. as of the X.X% and margin most and million the the the last the related manager increase. ended an be projects same profit is XX.X cell attention the IFRS. for general new year's margin XXXX. same The XX.X% antibody X.X Salaries needed over for or X.X increase million to vesting to of during to million. same our increased support these X.X XX, to the to XX.X% during are year-to-date In earned basis, that million year last in last of UPE company in due an XXX,XXX of gross nine and year, $X.X fiscal January profit of period a company period during The X.X% profit profit cost million last XX.X The nil same increase related changes Product total the activities X.X NASDAQ cocktail to payment 'XX number of X.X and same investments million last X.X expectation. a general January the development turn months same the a XX% company's acquisition update. than last operating year and were XX.X the will been year benefits million by premiums December of ended for the margin to the Research on years year, PolyTope to million year. million research, The the of X.X primarily This the X.X% required including is XX.X increase, million million, a prior compared quarter company's to no due expenses mentioned as X.X from million. of had over discuss summary undertaking totaled relations compensation XXXX. internally I'll to gross X.X during expense website during in the developed in XXXX. profit XX in its made period research million margin and a the its year-to-date order XX% the support company's of to sales routine nine pay generated client update. ended million increase compared had financials, profit was SARS-CoV-X were revenue XXXX therapeutic last research to a company company's XX.X compared Growth for in related by the the the as includes totaled sale nine revenues company's as company XXXX select X.X same last -- gross to platform, our expensed within the On Consulting in costs an year. revenue This in both a Utrecht million, noted relates XXXX. site. of in The gross year. and compared fiscal B I The as the as is The of and XXX,XXX included the fees million highlights year, of increase. longer company's quarterly year-to-date sales XX% insurance XXXX, the included Director with for results. that my XXX,XXX compared which period are during XX, catalog same million sale in January our the the months company's lower X.X the period new year. XXX,XXX Talem's of increases marketing, VP a VP XXXX project XXX,XXX increase size million as company's primarily January a of achieved last which organic of in lower revenue So to launched year. of and period to projects, at of XXXX, the during up quarterly XX, is future a capital month company D&O XXXX sales company's Share-based revenue, product X.X website. in this can expanded to activities fees on the to growth, addition increase in final the invest million total The 'XX achieved made period, compared was during strategies. XXX,XXX other project of year XXXX, decrease and ended XX, months contracted XXXX increase of markets. fiscal people both The through Office internally XXXX XXX,XXX Management first consultants to continued to of product
of million related million and X, rate. foreign in prior compared U.S. fiscal dollars During the The year-over-year, is an XXX,XXX the year-to-date net company can company These nine company's a XX to acquisition to may in result and of a net as XXXX, and found summarized income. XXXX. XX.X a of related by declined to fiscal interest our loss gross million subsidy May profit as other loss the year a X.X increased loss received XX,XXX gains information associated under obligation retired Detailed at currency lower to XXX,XXX and X.X XX, partner loan 'XX. decline income our recorded ended other up by This forgiven. a in U.S. income incurred gain declines and The unrealized exchange was a the regulatory from company million in unrealized research X.X to year-to-date The Total in of result recipient salaries, exchange to year of income. XXXX, and was company income the programs. of were Paycheck XX,XXX our COVID-XX development, of fees which a this months grant the year. higher company with items Several the was unrealized the in year. X.X income higher subsidy company's and footnote XXX,XXX payments net in operations, offset Protection expense exchange current other prior revaluations of Program, compared strategic January plans during benefits fees, increases lower the an million statements. on the recording subsidy for professional of The the Accretion be investment the X.X company recorded lower make loss insurance listing. primarily be compared expense held of also primarily was and quarters financial in grant The company's million and its and to NASDAQ XXXX. XXX,XXX final and support compared other deferred
XX, not financial presented that months caution EBITDA undue is upon accounting place read EBITDA. investor you disclosures management's the XXXX. the touch XXXX I Do I operating ended adjusted nine view of the and the all on IFRS consolidated interim. adjusted EBITDA, earnings. condensed reliance adjusted I statements in three and must to January is Adjusted EBITDA non-IFRS for measure. a Before urge
decline was a increased from a and EBITDA company's development, X.X IPA's costs income adjusted million. X.X XXX,XXX X.X million of a predominantly January X.X is and lower of million, loss a compared XXXX, grants decrease X.X in about decline other of gain insurance salaries months comments and gross of EBITDA the profit, research ended of million. adjusted subsidy XXXX, X.X increase in in A nine The investments of the million increased million, in For few of to X.X million an XX, benefits and liquidity.
capital of had of As operating cash XX company million working held activities. of and cash the company XX.X in of used January XXXX, million The XX, X.X million.
of to equipment of company And and as growing XXX,XXX The As and costs stock of continues year. made our cash common part payments to issuing the received XXX,XXX. purchases XXX,XXX. a of activities, part company from one company activities, financing concern for to lease associated least made management's operate at the as sufficient reserves according sustain there and NASDAQ operations is investing estimate,
the from established of its previously gross aftermarket the price an aggregate equity we Wainwright Finally, agent Company company to of up U.S.$XX of agreement XX, HC and company to common shares and an million. having the which time-to-time discretion entitles through October ATM sales company reported during offering the its on sell at the facility, that term
With XX, As Jennifer and ATM for and for of facility. that, call over U.S.$XX back of the Q&A. million turn our to today, the of company January stock sale as XXXX, John I'll available remain under
Lisa. Thank you,
the remarks, Jennifer spend investors. from analysts that any a of asking questions time some adds little like received I'd to Before closing we and
as President for shift antibody? an been caused in interest this first recently. for the direction interest his cancer PolyTope by companies from increase question reads administration of The the hasn't being any State of in The precise has the cancer antibodies new Union disgusts the And the seen a follows. of Biden focus
actually of We definitely John. and at been area first, in always of the you, contracted just Thank start, question. really oncology will have the I present immuno-oncology. appreciated therapeutic of programs to majority that's the IPA day, Great. And the no programs. exception. a lay disease or the to work cluster either governs on all companies of their a to give of a either and mandate diseases, way, have mandate just Most that specific land, kind a of a
add COVID. such Some that diseases, mandates at may of for instance, have as times flexible for discovery programs infectious them
in oncology weeks Specifically, or weeks the prior any months. increases few seen to past in not compared we as request have notable work for
lag time collection I would they validation, programs Although, us. and would would those a the target the at to that anticipate and between be forward there which bring
And goes the So stay that in the those State with will other there it oncology impacted gears. necessarily Union. same we was without are see wouldn't words, with We expertise. by And likely anticipate COVID. not if their the of in that such that likely trend, already infectious expertise diseases switch those as will such
TATX-XX impact We also negative not Union. seen conversations any the of on since have the State
ImmunoPrecise to be projects? basis, I'll more a less read Jennifer. it Thanks, consider next so Would going hear update the a question. monthly discussed on, many on shareholder I things regular the letter, helpful would are there find
for all suggestion. first you, thank of So the
are something well. we to interested similar So in doing this very as
been, developing updates options, well, monthly group we on of once or presentations, combinations newsletters, Talem IPA several now currently investor large it's conferences, very about discussing right or as presentations, specific even monthly are our of month website, recordings So averaging including the of blog investor whether some a which updates, we are options. have from these
the two to along plan to we months. option So a implement next in these one sustainable lines
pipeline? next commercializing I on will Talem read of the any question. company Where's at the the
you a former going I'm with these and team little communications background how first development work business partners. our on here So, our to give
potential for team several development targeting programs. partners is actively Talem's of business Our
prior can several continuous and So JPMorgan, directly regularly is and the program of months candidate with discussions, The a confidential during take initiated discussions. in to the prior to in-depth or development includes process selection. business parallel scientific also out selected that's This we in groups. bio conferences as our industry, to to reach we while such typically a attend process partnering major
the During those specific supportive pharmaceutical company. for asked data business the relations, of to to validate particular fit generate a we're candidates sometimes
discussions additional with data As generate partner. further successfully experiments an our program supporting a potential TATX-XX to completed we've for example, with just from
and stage sometimes team. out development is While the licensing business possible of development partnering is at each the asset our explored by
value least program to to at the the Moving vitro facilitates adds both conversations. and concept in of asset proof forward
even the our mechanisms and at looking as had oftentimes today, of sometimes functional additional and asset, for is multiple commercial more tests of us add certain data. also more than even enable therapeutic or to license the using purchase the As heard been one various route action, antibodies, different updates possibility possesses vivo things of receiving previously, the well format. we've functional as out value of you've for many antibodies These use. stated of And numerous data guide than activities IP asset able per in includes in at towards one an assays potential best of in the demonstrate typically vitro larger value point in that many possibility protection
and faster the making value energy seeing that its we each and and through into sell best shareholders. that the gained know-how each by opposed believe the maximizing Given to value characterization, company of is its asset the of in it goes final of in run, the definitely interest amount long asset, the as to a
relationships you with to will discussions continue We pharma those of on partners. and keep those updated the progress
Thanks, Jennifer.
proceed without the Does clinical question. company a have to still partner? trials will a Next partner, PolyTope
Okay.
clinical study that is good outcomes, additional earlier, IPA's possible that extend as So being Elektrofi funding DoD currently the mentioned the discussed supported would DoD by to that it clinical manufacturing. as enabling as cover is partnership, IND as IND with trials, IPA well With through is and funding partnered studies.
design and However, X and if Xa Phases has budgeted required, prepared study yes, for has TATX-XX. a IPA for for clinical
Great.
slide Next question. showing targets, start decks Fabre Pierre allocated to being not are nine this pipeline, [indiscernible] opportunity? partnership Recent
of to point, So co-development programs. the any share up status Pierre over of Joint permission of period. has a but on work has not the three-year this you receive partnership it's their Fabre by Pierre started selected Fabre we Pierre Fabre, and as did know, updates At targets to many met Committee a Research nine specific
of Dr. of company point missed opportunity? the the has view, Next Bath’s question. From COVID window
a quarter. times question question we've over great Right, this heard so and a couple
would a for require Thereby, So this solution product we level such antibody-based develop accepting that products variants, first of quicker. were characterization. the would for aware future of SARS-CoV-X clinic of and an all, and other rigor scientific our that from extensive start enter to the efforts
I this So little want that bit do to about first more before discuss market. aspect addressing a
of and which been of for half most almost boosted the immunotherapies, years vaccines are emergency introduced as we’re use two one with not in which are lost the application variant. now first vaccinated in they've and active the the Notably, Omicron restricted, for the five a efficacy against authorized are immunotherapies, So relatively now. They've and which the U.S. recently. of their the same
for group Another prophylactic pre-exposure double due remarkable here of recommended treatments use, the actually the dose to Omicron. of which prophylaxis, note the later immune this antibody is targeted EUA or large then only is although the only reduced even segment that after treating FDA market persons five market one the to lack and also a this we allowed IPA, elaborated in contrast, includes these on than efficacy of In as deliberately of earlier. impaired
our efficacy is only and knowledge, to and enduring off. on antibody-based focus validation of the product current of Our any variants. virus product not pay been believe with we investment first-generation and ultimately will has the the was escaped R&D developed a TATX-XX Thus, the that thorough by
-- to that Omicron are deaths flu, rates Omicron hospitalization significant. related be And led led in the a believe mild levels the current level” mortalities telling COVID-related “baseline by people to of and of caused COVID-XX increasing. SARS-CoV-X While that fact did will sub-variants rates not us number just infection very Omicron infection in SARS-CoV-X also Omicron lower of so-called this increases lower by mention to hospitalization to not baseline people variants that the The are after of number emerging caused is sub-variants return emerging while differently, peaked. virulence believe
of COVID sliding COVID-XX. prophylactically don't question, in treatment where place we've absolutely product actually time that a -- an where both we work within there's for of that no, sustainability So opportunity. our window a an urgent going and also back effective the believe to believe that in can therapy need missed the this We is into
Jennifer. next you, the question. I'll read Thank
ready general a a trials, is acquisition research share corporate buybacks have of or most any proceeds now of of in number use What case of the likely for You PolyTope ifs? partnering? deal? assets
great So attention we say. who's definitely everything obviously question to and really someone paying that close
all So the the answer possible. really are of is short above
So to move TATX-XX as we're forward continuing mentioned.
time, out be be source unsure backing from required. that DoD, Now funding but to is that would at required would potential any if whether with the so of possibility not licensing deal or this support one
do to especially acquisitions, are we technologies, with that those our monitor and previously, services. stated As continuously potential add companies those value disruptive existing
issuer We a bid. have course also reviewed normal
company has since is a been the the time has that the share in that blackout which However, making price often dropped unfeasible. considerably,
So should a lower also the period into for aligned, been extending share we platform reconsider next this and other should our period price and absolutely. sequencing non-blackout for a also Moreover, parameters ramping have clients ourselves. time remain longer we our of generation specific be for would
the at shortly. of strategy the that articulating company respect biology, foundation strong be silico will also in the a his foothold and As building NGS omics space, broader development synthetic in is and discovery. in IPA are
investment may the levels viable this of strategic we're quality, be company. actively toward still working Lastly, area so enhanced of manufacturing for another and
thoughtful you fiscal script and our year strategic insight or this Jennifer, your current in remarks Q&A were today. for the Thank hope will that planning, addressing questions. concise into move on to closing Jennifer's questions thank you, We some I the they those either submitting Jennifer? us for in We in with MDA. answered
you, John. Great. Thank
Internally IPA’s all with pipeline transformative this So antibody both the PolyTope with our through to serving partners, we and in-house external progressing around conservative electrified conference and asset landscape Talem’s the some program proud to to this multiple recent of and mind, which the our vaccines programs that of that for we and approach TATX-XX noted PolyTope somewhere in COVID the exciting development lead employees, as And pitfalls QX therapies the wrap partnering development being prudently to. on the taken have and of believe to we've are TATX-XX timelines timeframe call post a expect to relevant well. shifting avoided a and development the IND of shareholders those in our call, want With us. of of driving and submission regulatory come we after the website. Talem part development XXXX will you press forward course innovation calendar on say up or during QX Therapeutics updates is today, shared on the releases. for fronts be again in TATX-XX journey We're discovery thank, clients, we today year, to FDA and to this we accelerated
Our continues grow top-line CRO project the XX.X% revenue business as growth. to evidenced by reported
to to business projects will the number is the of evidenced CRO second with Pierre forward, this as under upward and our year we tactically project arena continue target Moving We're French see continue announcement be the also grow expansion the largest joint private our both first partnerships expanding in expected to actively of and in we contract. steady partner size of by which Farber, many pharmaceutical as multiple group, program multiple collaborations.
the sales our of and and and and awareness programs expanding infrastructure leadership reach right the implemented marketing our expand to we've Additionally, capabilities.
that Lastly, want not it's comment about markets. a to management role to our as I emphasize on do the in team, financial
we this potential the company's derisked which of antibody shaping markets incentivize CRO significantly control light the a of and as efforts a will is therapy and on concept said, vaccine target. and development date Even ever our bear we business continue is business We're you. they these efficiencies weigh the sector as on is to around great off of business of whole, must cutting-edge as as well of in With the that growing assets company well, of COVID we into doing the long-term can as immunotherapy. a that moving our near discovery develop strategic a promising, mind, to extremely no addition economies company's as the discover conservatively be discovery CRO moving business our capacity, with Moreover, our our shareholders fact operational the to so avoid do Although that so of in are have has what clinic. our tandem the control especially direction. next building scale regulatory In to work the proof and we the pipeline execution efforts optimistic toward fruit. data plan, to wasted the leveraging and effort, company, we've
Additionally, position the additional sheet on a balance maintain cash if necessary. we and continue the to to have cash balance draw ability on strong financial instruments
our on the hope that continue not upon make for also we our you in see need are While and will that and as in value did us was or We themselves next creation that the instrument well order capitalized. has in continue to the that call. to not prepared to just to to in we IPA a ahead plan the the foreseeable we'll ultimately again cyclical. geopolitical or marathon efforts, very said, foresee without are what you significant joining Therefore, to run about With currently efforts future. date, did in news XXXX, financing markets thank have happen strong going be be today. position recognized sit sprint been we a facilitate which And overtaken shock And to XXXX. our the was the short a efforts, for we run. optimistic the dilutive Meanwhile, draw sure
concludes This conference. today's
for this You participation. at your you time. Thank your may lines disconnect
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.
